Amicus Therapeutics Inc (0HF9.L)

Name: Amicus Therapeutics Inc Financial Statements
Creator: Quarter Results

Healthcare | Medical Pharmaceuticals

Latest reporting period: 2025-12-31

Latest Quarter

2025-12-31

Revenue

$185M

Net Income

$1.7M

Operating Margin

8.6%

Free Cash Flow

$29.8M

Debt / Assets

71.1%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Amicus Therapeutics Inc (0HF9.L).
Income Statement (Quarterly)	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Revenue	185,212,000	169,061,000	154,688,000	125,249,000
Cost of Revenue	28,444,000	21,341,000	15,217,000	11,698,000
Gross Profit	156,768,000	147,720,000	139,471,000	113,551,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	117,081,000	90,036,000	84,543,000	91,827,000
Operating Expenses	140,822,000	113,451,000	148,945,000	121,503,000
Operating Income	15,946,000	34,269,000	-9,474,000	-7,952,000
Interest Expense	11,428,000	11,711,000	11,565,000	11,455,000
Income Before Tax	3,143,000	34,274,000	-19,181,000	-18,045,000
Income Tax Expense	1,453,000	16,968,000	5,239,000	3,641,000
Net Income	1,690,000	17,306,000	-24,420,000	-21,686,000
Per Share
EPS	0.01	0.06	-0.08	-0.07
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Amicus Therapeutics Inc (0HF9.L).
Income Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue	634,210,000	528,295,000	399,356,000	329,233,000
Cost of Revenue	80,389,000	52,943,000	37,326,000	43,941,000
Gross Profit	553,821,000	475,352,000	362,030,000	285,292,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	383,487,000	323,379,000	275,270,000	213,041,000
Operating Expenses	519,330,000	450,476,000	427,651,000	489,718,000
Operating Income	34,491,000	24,876,000	-73,494,000	-204,426,000
Interest Expense	46,159,000	49,598,000	50,149,000	37,119,000
Income Before Tax	191,000	-28,756,000	-150,101,000	-242,039,000
Income Tax Expense	27,301,000	27,350,000	1,483,000	-5,471,000
Net Income	-27,110,000	-56,106,000	-151,584,000	-236,568,000
Per Share
EPS	-0.09	-0.18	-0.51	-0.82
EPS Diluted	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Amicus Therapeutics Inc (0HF9.L).
Balance Sheet (Quarterly)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Cash and Cash Equivalents	214,010,000	213,752,000	246,994,000	148,813,000
Short Term Investments	79,526,000	36,194,000	39,206,000	144,782,000
Net Receivables	115,307,000	101,099,000	87,632,000	66,196,000
Inventory	228,819,000	118,782,000	59,696,000	23,816,000
Total Current Assets	676,173,000	504,736,000	483,061,000	423,816,000
Property Plant Equipment	48,246,000	51,661,000	57,979,000	60,312,000
Goodwill and Intangibles	211,712,000	214,995,000	218,287,000	197,797,000
Total Assets	949,870,000	785,033,000	777,880,000	724,167,000
Liabilities
Account Payables	28,630,000	12,947,000	15,120,000	15,413,000
Short Term Debt	8,741,000	8,455,000	8,324,000	8,552,000
Total Current Liabilities	237,828,000	148,702,000	167,689,000	139,018,000
Long Term Debt	474,584,000	435,189,000	436,735,000	391,990,000
Total Liabilities	675,629,000	590,988,000	617,706,000	601,120,000
Shareholders Equity
Retained Earnings	-2,767,290,000	-2,740,180,000	-2,684,074,000	-2,532,490,000
Total Shareholders Equity	274,241,000	194,045,000	160,174,000	123,047,000

Balance sheet annual history for Amicus Therapeutics Inc (0HF9.L).
Balance Sheet (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Cash and Cash Equivalents	214,010,000	213,752,000	246,994,000	148,813,000
Short Term Investments	79,526,000	36,194,000	39,206,000	144,782,000
Net Receivables	115,307,000	101,099,000	87,632,000	66,196,000
Inventory	228,819,000	118,782,000	59,696,000	23,816,000
Total Current Assets	676,173,000	504,736,000	483,061,000	423,816,000
Property Plant Equipment	48,246,000	51,661,000	57,979,000	60,312,000
Goodwill and Intangibles	211,712,000	214,995,000	218,287,000	197,797,000
Total Assets	949,870,000	785,033,000	777,880,000	724,167,000
Liabilities
Account Payables	28,630,000	12,947,000	15,120,000	15,413,000
Short Term Debt	8,741,000	8,455,000	8,324,000	8,552,000
Total Current Liabilities	237,828,000	148,702,000	167,689,000	139,018,000
Long Term Debt	474,584,000	435,189,000	436,735,000	391,990,000
Total Liabilities	675,629,000	590,988,000	617,706,000	601,120,000
Shareholders Equity
Retained Earnings	-2,767,290,000	-2,740,180,000	-2,684,074,000	-2,532,490,000
Total Shareholders Equity	274,241,000	194,045,000	160,174,000	123,047,000

Cash flow quarterly history for Amicus Therapeutics Inc (0HF9.L).
Cash Flow Statement (Quarterly)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Operating Activities
Net Income	-27,110,000	-56,106,000	-151,584,000	-236,568,000
Depreciation & Amortization	2,570,000	8,547,000	7,873,000	5,342,000
Stock Based Compensation	87,410,000	84,905,000	86,077,000	76,512,000
Change in Working Capital	-39,633,000	-98,943,000	-47,990,000	-39,880,000
Operating Cash Flow	33,145,000	-33,891,000	-69,091,000	-166,575,000
Investing Activities
Capital Expenditure	-3,296,000	-3,553,000	-7,440,000	-3,766,000
Investments	-3,296,000	-3,553,000	-7,440,000	-3,766,000
Investing Cash Flow	-46,432,000	-560,000	98,064,000	92,316,000
Financing Activities
Debt Repayment	-272,000	-97,000	-20,958,000	-283,000
Common Stock Issued/Repurchased	19,205,000	27,243,000	92,935,000	-7,180,000
Dividends Paid	0	0	0	-7,463,000
Financing Cash Flow	610,000	5,121,000	61,677,000	-7,463,000
Summary
Free Cash Flow	29,849,000	-37,444,000	-76,531,000	-170,341,000
Net Change in Cash	600,000	-33,361,000	96,962,000	-96,384,000

Cash flow annual history for Amicus Therapeutics Inc (0HF9.L).
Cash Flow Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Operating Activities
Net Income	-27,110,000	-56,106,000	-151,584,000	-236,568,000
Depreciation & Amortization	2,570,000	8,547,000	7,873,000	5,342,000
Stock Based Compensation	87,410,000	84,905,000	86,077,000	76,512,000
Change in Working Capital	-39,633,000	-98,943,000	-47,990,000	-39,880,000
Operating Cash Flow	33,145,000	-33,891,000	-69,091,000	-166,575,000
Investing Activities
Capital Expenditure	-3,296,000	-3,553,000	-7,440,000	-3,766,000
Investments	-3,296,000	-3,553,000	-7,440,000	-3,766,000
Investing Cash Flow	-46,432,000	-560,000	98,064,000	92,316,000
Financing Activities
Debt Repayment	-272,000	-97,000	-20,958,000	-283,000
Common Stock Issued/Repurchased	19,205,000	27,243,000	92,935,000	-7,180,000
Dividends Paid	0	0	0	-7,463,000
Financing Cash Flow	610,000	5,121,000	61,677,000	-7,463,000
Summary
Free Cash Flow	29,849,000	-37,444,000	-76,531,000	-170,341,000
Net Change in Cash	600,000	-33,361,000	96,962,000	-96,384,000